摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 6-cyano-2-(2-(4-ethyl-3-(4-morpholinopiperidin-1-yl)-phenyl)propan-2-yl)-1H-indole-3-carboxylate

中文名称
——
中文别名
——
英文名称
tert-butyl 6-cyano-2-(2-(4-ethyl-3-(4-morpholinopiperidin-1-yl)-phenyl)propan-2-yl)-1H-indole-3-carboxylate
英文别名
Alectinib intermediate;tert-butyl 6-cyano-2-[2-[4-ethyl-3-(4-morpholin-4-ylpiperidin-1-yl)phenyl]propan-2-yl]-1H-indole-3-carboxylate
tert-butyl 6-cyano-2-(2-(4-ethyl-3-(4-morpholinopiperidin-1-yl)-phenyl)propan-2-yl)-1H-indole-3-carboxylate化学式
CAS
——
化学式
C34H44N4O3
mdl
——
分子量
556.748
InChiKey
ULNYFVQKXJYKEQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.6
  • 重原子数:
    41
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    81.6
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • METHOD FOR PREPARING ALECTINIB
    申请人:SUZHOU MIRACPHARMA TECHNOLPGY CO., LTD.
    公开号:US20170247352A1
    公开(公告)日:2017-08-31
    A method for preparing Alectinib (Alectinib, I), comprising the preparation steps: subjecting 6-cyano-1H-indole-3-carboxylate and 4-ethyl-3-(4-morpholine-4-yl-piperidine-1-yl)-α,α-dimethylbenzyl alcohol to condensation, hydrolyzing and cyclization reaction so as to prepare Alectinib (I). The preparation method has easily available raw materials and a simple process, and is economical and environmentally friendly and suitable for industrial production.
    一种制备阿雷替尼(Alectinib, I)的方法,包括以下制备步骤:将6-氰基-1H-吲哚-3-甲酸酯和4-乙基-3-(4-吗啡啉-4-基哌啶-1-基)-α,α-二甲基苄醇进行缩合、水解和环化反应,以制备阿雷替尼(I)。该制备方法具有原料易得、工艺简单、经济环保且适合工业生产的特点。
  • 一种艾乐替尼的制备方法
    申请人:湖南博奥德药业有限公司
    公开号:CN107033124B
    公开(公告)日:2019-09-20
    本发明公开了一种艾乐替尼的制备方法。该方法将2‑4‑乙基‑3‑[4‑(吗啉‑4‑基)哌啶‑1‑基]苯基}‑2‑甲基丙酸乙酯进行还原反应;将得到的2‑4‑乙基‑3‑[4‑(吗啉‑4‑基)哌啶‑1‑基]苯基}‑2‑甲基丙醛与2,2‑二氯乙酸叔丁酯进行加成重排反应;将得到的3‑氯‑4‑4‑乙基‑3‑[4‑(吗啉‑4‑基)哌啶‑1‑基]苯基}‑4‑甲基‑2‑氧代戊酸叔丁酯与间氨基苯甲腈进行取代反应;将得到的3‑(3‑氰基苯氨基)‑4‑4‑乙基‑3‑[4‑(吗啉‑4‑基)哌啶‑1‑基]苯基}‑4‑甲基‑2‑氧代戊酸叔丁酯进行环化反应和水解反应;将得到的6‑氰基‑2‑2‑[4‑乙基‑3‑(4‑(吗啉‑4‑基)哌啶‑1‑基)苯基]丙‑2‑基}‑1H‑吲哚‑3‑羧酸进行环化反应,得到艾乐替尼。该方法操作简化,成本较低,是一种绿色环保工艺方法,适用于工业化生产。
  • SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ALK INHIBITOR
    申请人:XU YONG
    公开号:US20160257667A1
    公开(公告)日:2016-09-08
    The present disclosure provides a method for preparing a compound of formula XVII, comprising: (1) contacting a compound of formula XIV with a compound of formula 3 to obtain a compound of formula 2; and (2) contacting the compound of formula 2 with a compound of formula 4 to obtain a compound of formula XVII. The method is low toxicity, cheap, easy to get, environmentally and friendly, and is economical and industrially applicable.
    本公开提供了一种制备化合物XVII的方法,包括:(1)将化合物XIV与化合物3接触以获得化合物2;(2)将化合物2与化合物4接触以获得化合物XVII。该方法毒性低、成本便宜、易获取、环保友好、经济实用,可在工业上应用。
  • METHOD OF PRODUCING TETRACYCLIC COMPOUND
    申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
    公开号:EP3848361A1
    公开(公告)日:2021-07-14
    This invention relates to a method for manufacturing 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile, and is industrially preferable, allowing an objective substance to be obtained in high yield more safely and easily than the conventional method.
    本发明涉及一种制造 9-乙基-6,6-二甲基-8-[4-(吗啉-4-基)哌啶-1-基]-11-氧代-6,11-二氢-5H-苯并[b]咔唑-3-甲腈的方法,与传统方法相比,该方法能够更安全、更容易地高产率获得目标物质,在工业上具有优越性。
  • Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure—activity relationship study
    作者:Xiaolong Jiang、Ji Zhou、Jing Ai、Zilan Song、Xia Peng、Li Xing、Yong Xi、Junfeng Guo、Qizheng Yao、Jian Ding、Meiyu Geng、Ao Zhang
    DOI:10.1016/j.ejmech.2015.10.005
    日期:2015.11
    Four series of tetracyclic benzo[b]carbazolone compounds possessing more rotatable bonds and higher molecular flexibility were designed by either inserting a linker within the C8-side chain or by opening the middle ketone ring on the basis of compound 5 (Alectinib, CH5424802). Compound 15b was identified showing nearly identical high potency against both wild-type and the gatekeeper mutant ALK kinase (3.4 vs 3.9 nM). This compound has favorable PK profile with an oral bioavailability of 67.1% in rats. Moreover, compound 15b showed significant growth inhibition against ALK driven cancer cells and KARPAS-299 xenograft model. (C) 2015 Elsevier Masson SAS. All rights reserved.
查看更多